Unmet needs remain in B-cell NHL, which will provide opportunities for developers, including the need for predictive and prognostic biomarkers, better therapies for relapsed or refractory
DLBCL, further options in FL for specific patient subsets, and therapies for MCL patients refractory to and relapsed after treatment with Imbruvica.
CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around USD 2.4bn in 2027.
Increasing prevalence, primarily by aging populations and the approval and launch of new branded therapies: lisocabtagene maraleucel, ublituximab with umbralisib, Blincyto, tafasitamab, Venclexta, and enzastaurin will drive market growth. FDA approved currently marketed therapies are:
- Yescarta
- Kymriah
- Polivy
- Revlimid
- Calquence
- Aliqopa
- Imbruvica
CAR-T therapies have been highly anticipated in NHL, and they are expected to improve treatment outcomes in heavily-treated patients, an area of major unmet need. While currently only approved for the DLBCL subtype, CAR-T therapies are expected to expand into FL, MZL and MCL, and earlier lines of therapy between 2017 and 2027.
B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027 report offers an overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
It also offers an insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to USD 9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 4.9%. The main driver of the growth will be the rise of chimeric antigen receptor (CAR) T cell therapies.
The growth of the B-cell NHL market will be tempered by the patent expiry of leading brands, including Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, and Velcade, and subsequent biosimilar/generic erosion. A major barrier for market growth in B-cell NHL, however, will be the increased use of biosimilars and generics, in particular, biosimilar rituximab. The branded Rituxan alone brought in around USD 2.5bn in the US in 2018.
Related Biotech Industry Articles